|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EX05
|
|
gptkbp:brand
|
gptkb:Cabometyx
gptkb:Cometriq
|
|
gptkbp:CASNumber
|
849217-68-1
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
orphan drug
|
|
gptkbp:developedBy
|
gptkb:Exelixis
|
|
gptkbp:eliminationHalfLife
|
99 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C28H24FN3O5
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
501.51 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
99.7%
|
|
gptkbp:PubChem_CID
|
25102847
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
vomiting
diarrhea
constipation
fatigue
hypertension
weight loss
decreased appetite
dysgeusia
stomatitis
hair color changes
|
|
gptkbp:target
|
gptkb:VEGFR
gptkb:KIT
gptkb:RET
gptkb:AXL
gptkb:TIE2
gptkb:MET
|
|
gptkbp:UNII
|
32P03S8Z6D
|
|
gptkbp:usedFor
|
gptkb:renal_cell_carcinoma
hepatocellular carcinoma
medullary thyroid cancer
|
|
gptkbp:bfsParent
|
gptkb:Exelixis
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cabozantinib
|